RLYB
NASD Rallybio Corporation$16.35 ↑ +0.00 (+0.00%) Trading Up from the previous close of $16.35, $0.08 below the day’s high of $16.43
- YTD change
- +197.88%
- vs 20-day SMA
- -3.15%
- vs 200-day SMA
- +31.82%
Price ranges
Price & Performance
+8.06 (+97.23%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 92.1% away from all-time highs of $206.24
- RLYB is up 198% since the beginning of the year
- RLYB is up 282% over the past 12 months
- RLYB is down 5% over the past 1 month
- 1% of all RLYB investors are betting against RLYB
RLYB reads neutral: price sits above one of the two key moving averages, the 12-month move is +2862.5%.
- Previous minute
- +$0.00
- Last hour
- -$0.25
- Last 5 days
- -3.94%
- vs 8-day SMA
- -2.69%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Rallybio Corp. engages in the identification, research and development, and manufacture of clinical biotechnology products and therapies for severe and rare diseases. Its product candidates focus on the areas of fetal and neonatal disorders, hematology, immuno-inflammation, and metabolic disease. The company was founded by Martin W. Mackay, Stephen Uden, and Jeffrey M. Fryer in January 2018 and is headquartered in New Haven, CT.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
